Showing results (1-10 of 83) with videos related to
Sort By:
Pageof 9
Oncogene|August 12, 2003
Virally targeted therapies for EBV-associated malignanciesBruce F Israel, Shannon C KenneyCancer Research|September 5, 2006
Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expressionWen-Hai Feng, Shannon C KenneyVirology|October 7, 2004
BZLF1, an Epstein-Barr virus immediate-early protein, induces p65 nuclear translocation while inhibiting p65 transcriptional functionThomas E Morrison, Shannon C KenneySeminars in Cancer Biology|January 25, 2014
Regulation of the latent-lytic switch in Epstein-Barr virusShannon C Kenney, Janet E MertzCell|September 16, 2022
Epstein-Barr virus: Biology and clinical diseaseBlossom Damania, Shannon C Kenney, Nancy Raab-TraubMolecular Immunology|June 16, 2009
CCAAT/enhancer binding proteins alpha and beta regulate the tumor necrosis factor receptor 1 gene promoterJillian A Bristol, Thomas E Morrison, Shannon C KenneyPlos Pathogens|February 21, 2012
The B-cell specific transcription factor, Oct-2, promotes Epstein-Barr virus latency by inhibiting the viral immediate-early protein, BZLF1Amanda R Robinson, Swee Sen Kwek, Shannon C KenneyJournal of Virology|December 13, 2003
Epstein-Barr virus immediate-early protein BZLF1 inhibits tumor necrosis factor alpha-induced signaling and apoptosis by downregulating tumor necrosis factor receptor 1Thomas E Morrison, Amy Mauser, Aloysius Klingelhutz, et al.Journal of Virology|September 28, 2012
The cellular ataxia telangiectasia-mutated kinase promotes epstein-barr virus lytic reactivation in response to multiple different types of lytic reactivation-inducing stimuliStacy R Hagemeier, Elizabeth A Barlow, Qiao Meng, et al.Journal of Virology|January 30, 2004
Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomasWen-hai Feng, Gregory Hong, Henri-Jacques Delecluse, et al.Pageof 9